Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2023.1232476OncologyCorrectionCorrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinomaLorussoDomenica12*DanesiRomano3LocatiLaura Deborah45MasiGianluca67De GiorgiUgo8GadducciAngiolo9PignataSandro10SabbatiniRoberto10SavareseAntonella11ValabregaGiorgio12ZamagniClaudio13ColomboNicoletta14151Department of Clinical Research Planning, Fondazione Policlinico Universitario A Gemelli Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Rome, Italy2Department of Life Science and Public Health, Catholic University of Sacred Heart, Rome, Italy3Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy4Translational Oncology Unit, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituti Clinici Scientifici (ICS) Maugeri, Pavia, Italy5Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy6Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy7Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy8Department of Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy9Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy10Department of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricerca e Cura a carattere scientifico (IRCCS) “Fondazione Giovanni Pascale”, Naples, Italy11Division of Medical Oncology 1, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) -Regina Elena National Cancer Institute, Rome, Italy12University of Torino-Struttura Complessa a Direzione Universitaria (S.C.D.U.) Oncologia Azienda Ospedaliera (A.O) Ordine Mauriziano-Ospedale Umberto I, Torino, Italy13Addarii Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy14School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy15Department of Oncological Gynecology, European Institute of Oncology (IEO) Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Milan, Italy
Edited and Reviewed by: Sophia George, University of Miami, United States
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma by Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C and Colombo N (2022) Front. Oncol. 12:979519. doi: 10.3389/fonc.2022.979519lenvatinibpembrolizumabendometrial cancertyrosine kinase inhibitorimmune responsesection-in-acceptanceGynecological Oncology
In the published article, there was an error in Figure 1 as published. By mistake, we added the reference 18 for this figure. The corrected Figure 1 and its caption appear below.
In the published article, an author name was incorrectly written as Sabbatini Roberto. The correct name is Roberto Sabbatini.
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Post hoc analysis of time to first onset of selected adverse reactions. Reproduced with permission from [19].